Wang Bing, Lassi Zohra, Andraweera Prabha, Chen Gang, Ong Jason J, McMillian Mark, Marshall Helen
Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia; Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
Robinson Research Institute, and School of Public Health, Faculty of Health and Medical Sciences, University of Adelaide, Australia.
Vaccine. 2025 Feb 27;48:126790. doi: 10.1016/j.vaccine.2025.126790. Epub 2025 Jan 29.
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants and can lead to severe respiratory distress, especially in very young infants. No specific treatments exist for RSV. However, new preventative strategies have become available including RSV vaccine for pregnant women and monoclonal antibody for infants. This study aimed to identify and understand barriers and facilitators to the uptake of a new RSV vaccine in pregnant women and determine their underlying choices for a maternal RSV immunisation program. Additionally, the study investigated choice for maternal vaccination or administration of a long-lasting monoclonal antibody to infants.
Eligible participants were pregnant women residing in Australia and aged 18 years or older. Focus group discussions and individual online interviews were conducted and data were analysed using a thematic analysis approach.
A total of 34 pregnant women participated in online focus group discussions or interviews, with an average age of 34 years. The identified themes were categorised into four overarching domains: 1) motivators for vaccinating during pregnancy to safeguard their babies and prevent severe diseases, 2) barriers to vaccination including vaccine safety concerns, uncertainties regarding vaccine effectiveness, and vaccine hesitancy arising from COVID-19 vaccination experiences, 3) preferred vaccination promotion strategies, including constant reminders/prompts, personalised messages, campaign focusing on serious outcomes and using diverse/lay languages, recommendations from local obstetricians and health authorities, 4) clear vaccine recommendation policies and a preference for maternal immunisation over infant immunisation.
The maternal RSV vaccination was generally welcomed and preferred by pregnant women in our study comparing to other strategies. Preferences for RSV program promotion included diversity in languages, "nudge" reminders, and recommendations from healthcare providers.
呼吸道合胞病毒（RSV）是婴儿毛细支气管炎和肺炎的主要病因，可导致严重的呼吸窘迫，尤其是对非常年幼的婴儿。目前尚无针对RSV的特效治疗方法。然而，新的预防策略已经出现，包括针对孕妇的RSV疫苗和针对婴儿的单克隆抗体。本研究旨在识别和了解孕妇接种新型RSV疫苗的障碍和促进因素，并确定她们对母体RSV免疫计划的潜在选择。此外，该研究还调查了孕妇接种疫苗或给婴儿注射长效单克隆抗体的选择。
符合条件的参与者为居住在澳大利亚、年龄在18岁及以上的孕妇。进行了焦点小组讨论和个人在线访谈，并采用主题分析方法对数据进行了分析。
共有34名孕妇参加了在线焦点小组讨论或访谈，平均年龄为34岁。确定的主题分为四个总体领域：1）孕期接种疫苗以保护婴儿和预防严重疾病的动机；2）接种疫苗的障碍，包括对疫苗安全性的担忧、疫苗有效性的不确定性以及因新冠疫苗接种经历而产生的疫苗犹豫；3）首选的疫苗推广策略，包括持续提醒/提示、个性化信息、关注严重后果并使用多种/通俗易懂语言的宣传活动、当地产科医生和卫生当局的建议；4）明确的疫苗推荐政策以及对母体免疫而非婴儿免疫的偏好。
在我们的研究中，与其他策略相比，孕妇对母体RSV疫苗接种普遍持欢迎和偏好态度。RSV计划推广的偏好包括语言多样性、“助推”提醒以及医疗保健提供者的建议。
